China
Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer
Jacobio Pharma (1167.HK) announced clinical results of its novel KRAS G12C inhibitor glecirasib monotherapy and in combination therapy with cetuximab to treat KRAS G12C mutant advanced CRC (colorectal cancer) in Second JCA- AACR Precision Medicine International Conference.
Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral ALPK1 Selective Kinase Inhibitor, DF-003
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective ALPK1 inhibitor for clinical evaluation.
Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA
Harbour BioMed (HKEX: 02142) announced that the National Medical Products Administration (NMPA) of China has accepted the Biologics License Application (BLA) of batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG).
Sanyou Forms Partnership with Hangzhou Zhongmei Huadong Pharmaceutical, Catalyzing Innovative Drug Research and Development
Recently, Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as Sanyou) and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963) (hereinafter referred to as Huadong Medicine), signed a license agreement for a collaboratively developed therapeutic biological product.
Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite
Caliway Biopharmaceuticals (Caliway), a Taiwan-based biopharmaceutical company focusing on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, today announced that the CBL-0201EFP Phase 2-Stage 1 results demonstrated the significant cellulite severity improvement with a single CBL-514 treatment.
Henlius Holds its 1st Overseas Scientific Advisory Board Meeting of 2023
Henlius successfully held its first Overseas Scientific Advisory Board (SAB) meeting of 2023 in California, United States.
Burning Rock Announces Resignation and Appointment of Directors
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR) announced the resignation of Dr. Shaokun (Shannon) Chuai as a director from the board of directors and as the Company’s Chief Scientific Officer, effective June 30, 2023.
Shineco Enters into Cooperation Agreement with Kangling Medical to Develop New Medical Products Company
Shineco, Inc. (NASDAQ: SISI), announced today that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd. signed a joint venture cooperation agreement with Yangzhou Kangling Medical Co., Ltd. to establish a joint venture company, Shangkang Life Science and Technology.
Aurisco gets Auxiton® (Dydrogesterone) as first generic approval in China
Aurisco Pharmaceutical received its first Marketing Authorization Approval in China for AUXITON®, the oral finished dosage form of Dydrogesterone, from China's Health Authority, the NMPA.
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
Sihuan Pharmaceutical Holdings Group Ltd together with its subsidiaries, announced that Xuanzhu Biopharmaceutical Co. received a drug registration approval from China's NMPA of Anaprozole Sodium Enteric-coated Tablet for the treatment of duodenal ulcer.
